Clinical Trials
2 trialsNCT05328102 2024-04-30
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)
Xencor, Inc.
Phase 2 Terminated
NCT00884546 2016-09-30
Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma
Bristol-Myers Squibb
Phase 1 Completed